Neovasc Inc. (NASDAQ:NVCN) is at $1.79 with a low of $1.67 and high of $1.80. This difference between the high and low classifies the stock as one of the most volatile of the day.
Company shares last traded at $1.79 well above the 50 day moving average which is $1.08 and which is significantly above the 200 day moving average of $1.38. The 50 day moving average was up by +66.22% and the 200 day average was up $0.41.
Traders are more bullish lately as inferred by the fall in short interest. The stock recorded a fall in short interest of -3.59% as of August 31, 2017 from the last reporting period. Short interest decreased 112,223 over that period. With short interest at 3,012,445 and short average daily volume at 178,829, the short-interest ratio is 17.0 and the percentage of shorted shares was 0.04% on August 31. As of the last earnings report the EPS was $-0.07 and is projected to be $-0.34 for the current year with 78,910,000 shares outstanding. Next quarter’s EPS is estimated at $-0.07 with next year’s EPS anticipated to be $-0.21.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular products worldwide. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch biological tissue products that are used as components in third-party medical products, such as transcatheter heart valves for industry partners and other customers. In addition, it offers a line of collagen-based surgical patch products for use in cardiac reconstruction and vascular repair procedures, as well as other surgeries. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada..